Investor Presentaiton slide image

Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T SLE Phase 2 results across endpoints provide rationale for Phase 3 100 SRI(4) response rates at week 481 A 22.7 (95% CI, 7.4-36.6) OR: 2.6 (95% CI, 1.4-4.8) Achievement of Lupus Low Disease Activity (LLDAS) at week 481 100 80 60 Response rate, % 50 60 40 40 20 20 P<0.001 57.1 47.3 47.2 34.4 0 n = 90 n = 91 n = 93 n = 89 Placebo deucravacitinib 3 mg BID 80 60 60 60 Δ 22.9 (95% CI, 9.6-35.3) OR: 4.0 (95% CI, 1.9-8.5) P<0.001 Response rate, % 40 20 20 36.3 25.8 23.7 13.3 n = 90 n = 91 n = 93 n = 89 0 deucravacitinib 6 mg BID deucravacitinib 12 mg QD Met the primary endpoint, and all secondary endpoints achieved or meaningfully improved at week 48 with a well tolerated safety profile consistent with earlier trials 1. Morand E, et al. Arthritis & Rheumatology. 2023 Feb;75(2):242-252.; Multiplicity-adjusted secondary end point; Primary endpoint was met: percentage of patients Ill Bristol Myers Squibb achieving SRI (4) at week 32 (P<0.001) Not for Product Promotional Use 62
View entire presentation